Major Breakthrough in the Fight against Cervical Cancer Presented at EUROGIN in Prague PR Newswire MENLO PARK, California, July 11, 2012 MENLO PARK, California, July 11, 2012 /PRNewswire/ -- Approximately 510,000 cases of cervical cancer are reported each year around the world, making it the second leading cause of cancer deaths among women worldwide. Yet, cervical cancer is treatable — and often curable — when detected in its early stages. IncellDx, a California-based research company, has introduced a new testing methodology called HPV OncoTect that measures a woman's increased risk for future development of cervical cancer with remarkable accuracy. Virtually all cases of cervical cancer are caused by specific types of human papillomavirus (HPV) and current testing methods detect only the presence and type of HPV infection and cellular abnormalities caused by the virus. OncoTect goes further to not only detect cellular transformation caused by persistent HPV infection, but also quantify the cancer causing genes found in the cells that is the necessary precursor to the development of cervical cancer. The new test was the focus of two independent clinical studies that sought to compare the performance of OncoTect against other commercially available tests.